The combination of ipilimumab with high dose IFNα2b (HDI) demonstrated an acceptable toxicity profile and a promising tumor response in ICB naïve patients (no treatment history of ICB) [348, 349]. This evidence concerns the gene IFNA2 and neoplasm.